Jun 1, 2025, 14:39
Christina Ip-Toma: Integrating germline and tumor genetic results to reduce disparities in cancer care
Christina Ip-Toma, Director of Scientific Programs at MIB Agents Osteosarcoma Alliance, shared on LinkedIn:
“Integrating germline and tumor genetic results is critical to reducing disparities and improving clarity in cancer care. A new Commentary in Nature Medicine offers insights from the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network. The commentary advocates for integrated genetic reporting frameworks to ensure that all patients, regardless of their tumor types, socioeconomic status, or ethnic background, have access to a comprehensive genetic assessment.
Read more here.
I am honored to contribute to the work of the Participant Engagement & Cancer Genome Sequencing (PE-CGS) Network and Cancer Genome Sequencing Network, funded by the National Cancer Institute (NCI). Our collective efforts are pivotal in closing the knowledge gap in cancer genomics. Thank you Alanna Church, Count Me In: Patient-Partnered Research and USC COPECC for your leadership and all contributors: Oindrila Bhattacharyya, Julie Culver, Jonathan Amzaleg, Erin Linnenbringer, Maeve Smart, Bethany Davis, Charité Ricker, Heinz Josef Lenz, Stacy W. Gray, Heather Hampel, David Wesley Craig. MIB Agents Osteosarcoma Alliance is grateful for this work that makes it better for all cancer patients.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 25, 2025, 22:49
Jun 25, 2025, 21:21